Lynozyfic’s global sales are projected to reach $707 million by 2031.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

The 17 sitting members of the Advisory Committee on Immunization Practices (ACIP) will be replaced by new members chosen by ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...